-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51

Benzinga·11/05/2026 16:12:19
Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $55 to $51.